Safety and Efficacy of the Combo Bio-engineered Sirolimus-eluting Stent Versus the Nano Polymer-free Sirolimus-eluting Stent in the Treatment of Patients With de Novo Stenotic Lesions

Inclusion Criteria: * Patients with clinical evidence of asymptomatic or symptomatic ischemic heart disease, stable or unstable angina, old myocardial infarction; * De novo lesions of native coronary arteries (lesions number ≤2); * Target lesion located in one or two different vessels. The number of target lesions in one vessel shall be no more than one; * Target vessel diameter between 2.5 and 4.0 mm by visual estimation. Target lesion length ≤ 32mm by visual estimation, which can be covered by one Combo stent with length 38mm or one Nano stent with length 36mm. It is suggested that the selected stent size should cover at least 2 mm (by visual estimation) of normal tissue on each side of the lesion; * Target lesion diameter stenosis ≥ 70% by visual estimation; * Each target lesion is permitted to implant only one stent at most, except bailout stent; * Patients is eligible for PCI and is an acceptable candidate for CABG; * Patients with left ventricular ejection fraction (LVEF) ≥40%; * Patients who can understand the nature of the study, agree to participate and accept angiographic and clinical follow-up, and have provided written informed consent; Exclusion Criteria: * Patients with acute myocardial infarction (AMI) within one week; * Chronic total occlusion lesion (TIMI 0 flow), Left main disease, Ostial lesion, and/or triple-vessel lesion that might require treatment, bifurcation lesions with a side branch diameter \>2.5mm or graft lesions; * Heavily calcified or tortuo…